HCG (Mid Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
HealthCare Global Enterprises Limited |
|||
|
Price: ₹474.80 | ||
| 52 Week Low: ₹314.00 52 Week High: ₹548.00 |
|||
| Market Capital: 6,551.18 Crore (Midcap) | |||
| Healthcare -> Medical Care Facilities | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: HCG Share Price Target For 2024
- 1.1.1: HCG Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: HCG Share Price Target For 2025
- 1.2.1: HCG Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: HCG Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: HCG Brief Company Overview
- 4: HCG Financial Performance
- 4.0.1: Is HCG A Good Buy For Long Term?
To predict the HCG's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
HCG Share Price Target For 2024
The line chart displays the monthly closing prices of HCG with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for HCG shares in 2024, see the table below.
HCG Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 526.05 (+10.79%) | Price Action: 19 Dec 2024 Low |
| 2024 Target 2 | 520.15 (+9.55%) | Price Action: 18 Dec 2024 Low |
| 2024 Target 1 | 514.4 (+8.34%) | Price Action: 03 Dec 2024 High |
| Current Price | 474.80 | HCG's share price as of 23 Dec 2024 |
| Stop Loss 1 | 493.1 (+3.85%) | Price Action: 12 Dec 2024 Low |
| Stop Loss 2 | 486.89 (+2.54%) | Price Action: 25 Nov 2024 High |
| Stop Loss 3 | 480.0 (+1.09%) | Price Action: 26 Nov 2024 High |
Short-Term Technical Outlook
Current Technical Position: HCG is showing mixed momentum signals near key moving averages.
Key Technical Level: The 50-day moving average at ₹473.73 serves as the nearest technical reference point.
Historical Returns: 3-month: +26.74% | 6-month: +39.82% | 1-year: +45.36%
HCG Share Price Target For 2025
The line chart displays the monthly closing prices of HCG with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for HCG shares in 2025, see the table below.
HCG Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 677.41 (+42.67%) | Price Action: Chart |
| 2025 Target 2 | 664.78 (+40.01%) | Fibonacci Extension Level 150.00% |
| 2025 Target 1 | 651.77 (+37.27%) | Fibonacci Extension Level 64.90% |
| Current Price | 474.80 | HCG's share price as of 23 Dec 2024 |
| Stop Loss 1 | 464.35 (-2.21%) | Price Action: 07 Nov 2024 Low |
| Stop Loss 2 | 458.52 (-3.43%) | Fibonacci Retracement Level 38.20% |
| Stop Loss 3 | 453.79 (-4.43%) | Price Action: 01 Nov 2024 High |
Long-Term Technical Outlook
52-Week Range Analysis: HCG is currently trading at 68.7% of its 52-week range (₹314 - ₹548).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +45.36% | 3-year: +122.25% | 5-year: +408.91%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
HCG Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹474.80 | ||
| 2024 | ₹469.48 | -1.12% | ₹476.52 |
| 2025 | ₹632.14 | +34.64% | ₹641.62 |
| 2026 | ₹732.66 | +15.9% | ₹753.86 |
| 2027 | ₹944.98 | +28.97% | ₹959.15 |
| 2028 | ₹1,059.10 | +12.07% | ₹1,074.99 |
| 2029 | ₹1,216.35 | +14.84% | ₹1,234.60 |
| 2030 | ₹1,395.03 | +14.68% | ₹1,415.96 |
| 2031 | ₹1,444.94 | +3.57% | ₹1,521.84 |
| 2032 | ₹1,714.12 | +18.62% | ₹1,739.83 |
| 2033 | ₹1,800.45 | +5.03% | ₹1,827.46 |
| 2034 | ₹1,963.22 | +9.04% | ₹1,992.67 |
| 2035 | ₹2,157.93 | +9.91% | ₹2,190.30 |
| 2036 | ₹2,157.22 | -0.03% | ₹2,290.98 |
| 2037 | ₹2,483.27 | +15.11% | ₹2,520.52 |
| 2038 | ₹2,541.80 | +2.35% | ₹2,579.93 |
| 2039 | ₹2,680.97 | +5.47% | ₹2,730.10 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
HCG Brief Company Overview
HealthCare Global Enterprises Limited HealthCare Global Enterprises Limited, established in 1989, is a leading healthcare service provider focused on cancer and fertility. Headquartered in Bengaluru, India, the company has a strong presence in the industry. Key Products and...
Services: Cancer diagnosis and treatment through radiation therapy, medical oncology, and surgery Fertility treatment, assisted reproduction, gynecological endoscopy, and fertility preservation Multi-specialty hospital services under the HCG brand Medical diagnostic services Reputation and Commitment: HealthCare Global has earned a strong reputation for providing high-quality healthcare services. The company is committed to delivering compassionate and effective care to its patients. Diverse Product Range: The company's diverse product range caters to a wide range of healthcare needs. Its services include cancer treatment, fertility treatments, and multi-specialty hospital services.HCG Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 6,551.18 Crore | Market valuation of HCG's shares. |
| Revenue (TTM) | 2,043.61 Crore | Total revenue generated by HCG over the past twelve months. |
| Net Income (TTM) | +57.04 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +9.49% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +2.79% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+13.7% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+32.6% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
172.04 | Company's total debt divided by total shareholder equity. |
| Total Debt | 1,557.94 Crore | Sum of HCG's current & long-term financial obligations. |
| Total Cash | 290.14 Crore | Total amount of liquid funds available to HCG. |
| Beta | 0.28 | Beta is less than 1 indicating that the HCG's price is less volatile than the market. |
Is HCG A Good Buy For Long Term?
HCG, a mid-cap stock with a market capitalization of ₹6,551.18 Crore, shows strong growth with 26.41% returns over the past year and impressive multi-year returns. However, a significant debt of ₹1,557.94 Crore (Q2 2024-25) against a cash balance of ₹290.14 Crore raises concerns. While the 32.6% rise in Q2 earnings compared to last year is positive, a low profit margin of 2.79% needs attention. Considering the high debt and relatively low profit margin, HCG is an average buy for the long term, requiring further due diligence to assess risk.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
